Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines

International Journal of Oncology

Volumn 27, Issue 3, 2005, Pages 791-798

  Onisto, Maurizio ^a   Slongo, M Liliana ^a   Gregnanin, Laura ^a   Gastaldi, Tamara ^b   Carli, Modesto ^b   Rosolen, Angelo ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Angiogenesis; In vitro invasiveness; Matrix metalloproteinases; Rhabdomyosarcoma; Vascular endothelial growth factor

Indexed keywords

COLLAGEN; DNA BINDING PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO1A PROTEIN, HUMAN; GELATINASE A; HYBRID PROTEIN; LAMININ; MATRIGEL; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 PROTEIN, HUMAN; PROTEOGLYCAN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER INVASION; CELL DIFFERENTIATION; CELL LINE; CELL MOTION; CULTURE MEDIUM; CYTOLOGY; DRUG COMBINATION; DRUG EFFECT; EMBRYONAL RHABDOMYOSARCOMA; ENDOTHELIUM CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN; CULTURE MEDIA, CONDITIONED; DNA-BINDING PROTEINS; DRUG COMBINATIONS; ENDOTHELIAL CELLS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; METALLOPROTEASES; NEOPLASM INVASIVENESS; PAIRED BOX TRANSCRIPTION FACTORS; PLASMIDS; PROTEOGLYCANS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSCRIPTION FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 24344448690     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Merlino G and Helman LJ: Rhabdomyosarcoma: working out the pathways. Oncogene 18: 5340-5348, 1999.
2. Wijnaendts LCD, van Der Linden JC, van Unnik AJM, Delemarre JFM, Voute PA and Meijer CJLM: Histopathological classification of childhood rhabdomyosarcoma: relationship with clinical parameters and prognosis. Hum Pathol 25: 900-907, 1994.
3. Anderson J, Gordon A, Pritchard-Jones K and Shipley J: Genes, chromosomes and rhabdomyosarcoma. Genes Chromosomes Cancer 26: 275-285, 1999.
4. Lam PY, Sublett JE, Hollenbach AD and Roussel MF: The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeo domain recognition helix but not the Pax3 paired-box DNA binding domain. Mol Cell Biol 19: 594-601 1999.
5. Anderson J, Ramsay A, Gould S and Pritchard-Jones K: PAX3- FKHR induces morphological changes and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol 159: 1089-1096,2001.
6. Liotta LA and Kohn EC: The microenvironment of the tumourhost interface. Nature 411: 375-379, 2001.
7. Stetler-Stevenson WG and Yu A: Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 11: 143-152,2001.
8. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
9. Ferrara N, Gerber HP and Le Couter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
10. Masood R, Cai J, Zheng T, Smith DL, Hinton DR and Gill PS: Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98: 1904-1913,2001.
11. Steiner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S and Herold-Mende C: Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J NeurooncoI66: 129-138,2004.
12. Kleiner DE and Stetler-Stevenson WG: Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218: 325-329, 1994.
13. Caenazzo C, Onisto M, Sartor L, Scalerta R, Giraldo A, Nitti D and Garbisa S: Augmented membrane type 1 matrix metalloproteinase (MTl-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. Clin Cancer Res 4: 2179-2186, 1998.
14. Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, Lewalle JM, Li H, Deroanne CF, Lu E, Colige A, Nusgens BV, Frankenne F, Maron A, Yeh P, Perricaudet M, Chang Y, Soria C, Carlberg- Bacq CM, Foidart JM and Noel A: Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase- 2 effect on in vivo mammary tumor growth and angiogenesis. Cancer Res 61: 3450-3457, 2001.
15. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozwloski JM and McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239-3245, 1987.
16. Zimrin AB, Villeponteau B and Maciag T: Models of in vitro angiogenesis: endothelial cell differentiation on fibrin but not matrigel is transcriptionally dependent. Biochem Biophys Res Commun 213: 630-638, 1995.
17. Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostor AG, Nie G, Lopata A and Salamonsen LA: Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 94: 1466-1475, 2002.
18. Ozen O, Krebs B, Hemmerlein B, Pekrun A, Kretzschmar H and Herms J: Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance. Clin Cancer Res 10: 4746-4753, 2004.
19. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, van Westrum SS, Crabbe T, Clements J, d'Ortho MP and Murphy G: The TIMP2 membrane type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 273: 871-880, 1998.
20. Ito S, Fukusato T, Nemoto T, Sekihara H, Seyama Y and Kubota S: Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancer. J Natl Cancer Inst 94: 1080-1091,2002.
21. Jankowski K, Kucia M, Wysoczynski M, Reca R, Zhao D, Trzyna E, Trent J, Peiper S, Zembala M, Ratajczak J, Houghton P, Janowska-Wieczorek A and Ratajczak MZ: Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 63: 7926-7935, 2003.
22. Diomedi-Camassei F, Boldrini R, Rava L, Donfrancesco A, Boglino C, Messina E, Dominici C and Cailea F: Different pattern of matrix metalloproteinases expression in alveolar versus embryonal rhabdomyosarcoma. J Pediatr Surg 39: 1673-1679,2004.
23. Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M, Marquez L, Peiper SC, Barr FG, Janowska- Wieczorek A and Ratajczak MZ: CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 100: 2597-2606, 2002.
24. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips H and Ferrara N: Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
25. Chan AS, Leung SY, Wong MP, Yuen ST, Cheung N, Fan YW and Chung LP: Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 22: 816-826, 1998.
26. Herold-Mende C, Steiner HH, Andi T, Riede D, Buttler A, Reisser C, Fusenig NE and Mueller MM: Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest 79: 1573-1582, 1998.